Arrowhead Q3 net loss $170.8M ($1.38/sh); secures $500M credit facility; plozasiran Phase 3 meets endpoints

ARROWHEAD PHARMACEUTICALS, INC.

2024-Q3 EPS reported -$3.63 revenue$3,551,000

Net loss of $170.8M ($1.38 diluted EPS) vs $102.9M ($0.96) a year ago; revenue nil vs $15.8M.
Secured $500M non-dilutive credit facility from Sixth Street ($400M funded, $100M available) plus $50M milestone from Royalty Pharma.
Pivotal Phase 3 PALISADE study of plozasiran in FCS met primary endpoint: triglycerides reduced up to 80%, APOC3 up to 94%, acute pancreatitis incidence reduced vs placebo.
Initiated Phase 3 SHASTA-3/4 for plozasiran in severe hypertriglyceridemia; plans for Phase 3 CAPITAN cardiovascular outcomes trial.
Cash and investments $436.7M at June 30, 2024, up from $403.6M at Sept 30, 2023; company approaching plozasiran launch in 2025 if approved.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.